Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cerebrospinal fluid, imaging and blood based biomarkers can provide critical information for dose selection, patient enrichment and supplementary evidence of disease modification in current clinical trials testing experimental therapeutics for Alzheimer's disease (AD). The current treatise provides examples of biomarker strategies utilized in AD clinical trial practice and highlights recent advances towards the identification of non-invasive approaches for enrichment and diagnosis. © 2013 Elsevier Ltd. All rights reserved.

Original publication




Journal article


Drug Discovery Today: Therapeutic Strategies

Publication Date